Pharmacokinetic-pharmacodynamic evaluation of gepotidacin against Gram-positive organisms using data from murine infection models
CC Bulik, ÓO Okusanya, EA Lakota… - Antimicrobial Agents …, 2017 - Am Soc Microbiol
Gepotidacin (formerly called GSK2140944) is a novel triazaacenaphthylene bacterial
topoisomerase inhibitor with in vitro activity against conventional and biothreat pathogens …
topoisomerase inhibitor with in vitro activity against conventional and biothreat pathogens …
Gepotidacin Pharmacokinetics-Pharmacodynamics against Escherichia coli in the One-Compartment and Hollow-Fiber In Vitro Infection Model Systems
BD VanScoy, EA Lakota, H Conde… - Antimicrobial Agents …, 2021 - Am Soc Microbiol
Gepotidacin is a novel, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial
DNA replication by a distinct mechanism of action with an in vitro spectrum of activity that …
DNA replication by a distinct mechanism of action with an in vitro spectrum of activity that …
Gepotidacin (GSK2140944) In Vitro Activity against Gram-Positive and Gram-Negative Bacteria
RK Flamm, DJ Farrell, PR Rhomberg… - Antimicrobial agents …, 2017 - Am Soc Microbiol
Gepotidacin is a first-in-class, novel triazaacenaphthylene antibiotic that inhibits bacterial
DNA replication and has in vitro activity against susceptible and drug-resistant pathogens …
DNA replication and has in vitro activity against susceptible and drug-resistant pathogens …
Cellular pharmacokinetics and intracellular activity of gepotidacin against Staphylococcus aureus isolates with different resistance phenotypes in models of cultured …
F Peyrusson, PM Tulkens… - Antimicrobial Agents and …, 2018 - Am Soc Microbiol
ABSTRACT Gepotidacin (GSK2140944), a novel triazaacenaphthylene bacterial
topoisomerase inhibitor, is currently in clinical development for the treatment of bacterial …
topoisomerase inhibitor, is currently in clinical development for the treatment of bacterial …
Pharmacokinetics of oral formulations of gepotidacin (GSK2140944), a triazaacenaphthylene bacterial type II topoisomerase inhibitor, in healthy adult and adolescent …
A Barth, M Hossain, DB Brimhall, CR Perry… - Antimicrobial Agents …, 2022 - Am Soc Microbiol
Gepotidacin is a novel, first-in-class triazaacenaphthylene antibiotic that may provide a new
treatment option for antibiotic-resistant pathogens. Two pharmacokinetic evaluations of oral …
treatment option for antibiotic-resistant pathogens. Two pharmacokinetic evaluations of oral …
Efficacy of Human Exposures of Gepotidacin (GSK2140944) against Escherichia coli in a Rat Pyelonephritis Model
JL Hoover, CM Singley, P Elefante… - Antimicrobial Agents …, 2019 - Am Soc Microbiol
Gepotidacin is a first-in-class triazaacenaphthylene antibacterial that inhibits bacterial type II
topoisomerases and has in vitro activity against a range of bacterial pathogens, including …
topoisomerases and has in vitro activity against a range of bacterial pathogens, including …
In Vitro Activity and Microbiological Efficacy of Gepotidacin from a Phase 2, Randomized, Multicenter, Dose-Ranging Study in Patients with Acute Bacterial Skin and …
NE Scangarella-Oman, KA Ingraham… - Antimicrobial Agents …, 2020 - Am Soc Microbiol
ABSTRACT A phase 2 study of gepotidacin demonstrated the safety and efficacy of 3
gepotidacin doses (750 mg every 12 h [q12h], 1,000 mg q12h, and 1,000 mg every 8 h …
gepotidacin doses (750 mg every 12 h [q12h], 1,000 mg q12h, and 1,000 mg every 8 h …
In Vitro Activity of Gepotidacin against Gram-Negative and Gram-Positive Anaerobes
MA Hackel, JA Karlowsky, MA Canino… - Antimicrobial Agents …, 2022 - Am Soc Microbiol
Gepotidacin (formerly GSK2140944) is a first-in-class triazaacenaphthylene antibacterial
currently in phase III clinical trials. When tested against Gram-negative (n= 333) and Gram …
currently in phase III clinical trials. When tested against Gram-negative (n= 333) and Gram …
In Vitro Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens
DJ Biedenbach, SK Bouchillon, M Hackel… - Antimicrobial agents …, 2016 - Am Soc Microbiol
Gepotidacin inhibits bacterial DNA replication through a mode different from that of
fluoroquinolones. Gepotidacin and comparators were tested by broth and agar dilution …
fluoroquinolones. Gepotidacin and comparators were tested by broth and agar dilution …
Pharmacokinetics of gepotidacin in renal impairment
M Hossain, C Tiffany, A Raychaudhuri… - … in drug development, 2020 - Wiley Online Library
Gepotidacin is a novel triazaacenaphthylene bacterial topoisomerase inhibitor. In this phase
1, nonrandomized, open‐label, parallel‐group, multicenter, multipart study, the …
1, nonrandomized, open‐label, parallel‐group, multicenter, multipart study, the …